Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1521 | Favipiravir plus Nitazoxanide Wiki | 1.00 |
| drug3670 | Sofosbuvir/daclatasvir Wiki | 1.00 |
| drug353 | Artesunate-amodiaquine Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D055370 | Lung Injury NIH | 0.19 |
| D013577 | Syndrome NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This exploratory study is a randomized, single center, open label study of four different experimental treatment arms versus standard of care for the treatment of SARS-CoV-2 infection in symptomatic outpatients with mild disease at the time of enrollment.
Description: Defined as the proportion of participants with a negative nasal swab
Measure: Incidence of SARS-CoV-2 clearance Time: Day 7Description: Defined as the proportion of participants with a negative nasal swab
Measure: Incidence of SARS-CoV-2 clearance Time: Day 10, 14, 21, 28Description: Defined as a negative swab
Measure: Time to clearance of nasal SARS-CoV-2 Time: Day 0, 3, 7, 10, 14, 21, 28Description: Detected from mid-nasal swabs by PCR
Measure: Median quantity of SARS-CoV-2 Time: Day 14Description: Number of days with fever
Measure: Proportion of days with fever after randomization Time: Day 28Description: Number of days with respiratory symptoms
Measure: Proportion of days with respiratory symptoms after randomization Time: Day 28Description: FLU-PRO© Plus questionnaire scores and FLU-PRO© Plus Global Additional Daily Diary Items *The Influenza Patient-Reported Outcome instrument (FLU-PRO© Plus)
Measure: FLU-PRO© Plus Time: 14 daysDescription: Serious adverse events
Measure: Serious adverse events Time: Day 28Description: Adverse events
Measure: Adverse events resulting in treatment discontinuation Time: Day 28Description: Related adverse events
Measure: Adverse events considered related to the investigational products Time: Day 28Description: Resting SpO2<93% sustained for 2 readings 2 hours apart AND presence of subjective dyspnea or cough in participants with access to SpO2
Measure: LRTI Time: Day 28Description: score 0(Uninfected)~ score 8(Dead)
Measure: Maximum score on WHO Ordinal Scale for Clinical Improvement during study participation Time: Day 28Description: frequency of patients requiring time in hospital
Measure: Cumulative incidence of hospitalization Time: Day 28Description: length of hospital stay
Measure: Days of hospitalization Time: Day 28Description: incidence of death
Measure: Cumulative incidence of mortality Time: Day 28 or later if participant is hospitalized at the time of Day 28Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports